Smart Money Group LLC Has $501,000 Holdings in Novo Nordisk A/S (NYSE:NVO)

Smart Money Group LLC decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 21.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 5,829 shares of the company’s stock after selling 1,593 shares during the period. Smart Money Group LLC’s holdings in Novo Nordisk A/S were worth $501,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA boosted its holdings in shares of Novo Nordisk A/S by 2.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 77,494 shares of the company’s stock valued at $11,061,000 after buying an additional 1,860 shares during the last quarter. Hsbc Holdings PLC raised its position in Novo Nordisk A/S by 19.4% during the second quarter. Hsbc Holdings PLC now owns 54,804 shares of the company’s stock worth $7,852,000 after acquiring an additional 8,922 shares in the last quarter. King Luther Capital Management Corp grew its position in shares of Novo Nordisk A/S by 11.7% in the 2nd quarter. King Luther Capital Management Corp now owns 28,171 shares of the company’s stock valued at $4,021,000 after acquiring an additional 2,960 shares during the period. AE Wealth Management LLC increased its stake in shares of Novo Nordisk A/S by 161.5% during the 2nd quarter. AE Wealth Management LLC now owns 19,319 shares of the company’s stock worth $2,758,000 after purchasing an additional 11,930 shares during the last quarter. Finally, Merriman Wealth Management LLC lifted its stake in Novo Nordisk A/S by 6.7% in the 2nd quarter. Merriman Wealth Management LLC now owns 2,325 shares of the company’s stock valued at $332,000 after purchasing an additional 145 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the topic of several research analyst reports. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $78.74 on Monday. The firm has a 50-day moving average price of $97.76 and a two-hundred day moving average price of $117.05. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The company has a market capitalization of $353.33 billion, a P/E ratio of 25.48, a P/E/G ratio of 0.92 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.